Alliances Announces 2021 State of the Science Summit
With a commitment to invest $30 million toward innovative and life-saving research by 2024, the Colorectal Cancer Alliance is taking a nuanced look at colorectal cancer research today to understand where it can have the greatest impact tomorrow.
The 2021 State of the Science Summit, set to meet virtually on October 4, is a last step in the Alliance’s research-field analysis before charting a five-year plan that will come to define its scientific strategy.
The summit will bring together multidisciplinary experts to collaboratively align on priority areas of research innovation and opportunity for colorectal advancements.
“We are looking for research domains where the Alliance can have the largest return on investment, answer questions that matter to patients, and ultimately save the most lives,” said Andrea Goodman, MSW, MPH, the Alliance’s Vice President of Patient Support and Research Strategy. “To do so, we are listening to patients, providers, and experts from every corner of the research community to understand where the greatest needs exist.”
Based on a forthcoming research landscape analysis commissioned by the Alliance, the summit will solicit detailed feedback in these areas, among others:
- Advancing new diagnostics and biomarkers
- Identifying new targets and improving therapies
- Overcoming health disparities and expanding screening
The need for research resulting in improved outcomes for colorectal cancer patients is clear. Despite significant advances in both the treatment and prevention of colorectal cancer, in the U.S. alone, more than 1.3 million people are living with a history of colorectal cancer in 2021. This includes approximately 150,000 new cases and 53,000 deaths this year.
A public report from the summit, which is invite-only, will be available in early November.
Top resources
Alliance and GCAR Announce Collaboration to Advance a Groundbreaking Adaptive Clinical Trial Platform for CRC: KLEOS
A first-of-its-kind trial platform in the colorectal cancer space, Project Cure CRC’s KLEOS is being driven by the Colorectal Cancer Alliance, the leading nonprofit dedicated to ending the disease, in collaboration with GCAR, a pioneer in the design and implementation of innovative clinical trials.
A blood test that sees what scans can't
For many cancer patients, the end of active treatment brings a new kind of dread. Scans every few months and anxious waits for results. A blood test is changing that experience for a growing number of patients.
HAI therapy proves pivotal for pioneering patient
When Helen was diagnosed with metastatic colorectal cancer, the biggest concern for her medical team was that her cancer had spread to her liver. One type of therapy, hepatic artery infusion, offered a path forward, but there was a catch. Nobody at her hospital had ever done it before. She'd have to be first.